Edwards fined $10m for skirting antitrust rules in JC Medical deal
Edwards Lifesciences must pay a record $10m penalty after a court found it illegally structured an acquisition to dodge antitrust review, a failed strategy that ultimately cost the company a subsequent deal.
Edwards Lifesciences has agreed to pay a $10m penalty to settle a court ruling that found the medical device maker violated antitrust laws when it acquired JC Medical in August 2024.
The US Federal Trade Commission argued that Edwards deliberately split the purchase price to avoid triggering mandatory regulatory reviews. The company paid Genesis Medtech, JC Medical's Singapore-based parent, $115m upfront while simultaneously pledging a separate $25m investment into Genesis. By treating these as independent transactions, Edwards kept the formal acquisition value just below the $119.5m threshold that would have required a filing under the Hart-Scott-Rodino Act.
That mandatory waiting period exists specifically to give federal antitrust agencies time to investigate deals and block anticompetitive mergers before they close. Edwards did not publicly announce the JC Medical transaction at the time, ensuring regulators remained unaware of the deal until it was finalized.
The urgency behind this obscured deal structure became clear the following day. Immediately after the JC Medical acquisition closed, Edwards entered into an agreement to purchase JenaValve, JC Medical's primary competitor. Owning both companies would have given Edwards control over the two most advanced developers of transcatheter aortic valve replacement systems for the emerging aortic regurgitation market.
The strategy ultimately failed. The FTC sued to stop the JenaValve acquisition in August 2025, citing anti-competitive concerns, and a court approved an injunction in January 2026. For investors, the sequence represents a significant strategic misstep: Edwards spent $115m on JC Medical but is now legally barred from consolidating the nascent TAVR-AR space.
JC Medical will pay an additional $2m, bringing the total penalty to $12m. The FTC noted this is the largest financial penalty ever levied for failing to make an HSR filing. "Companies that try to sneak deals through without lawful FTC review should take notice," said FTC chairman Andrew Ferguson. "The FTC will be vigilant in enforcing the requirements of the Hart-Scott-Rodino Act and we will not hesitate to seek penalties for its violation."
Beyond the financial hit, the District Court of Columbia's ruling mandates that Edwards establish a formal antitrust compliance programme. For corporate dealmakers and M&A lawyers, the case establishes a clear precedent that regulators will aggressively punish attempts to artificially fragment deal values to bypass review thresholds.
